• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search
Home » Scientific Evidence » Congress Publications

Congress Publications

The following is a list of scientific abstracts, posters and presentations on our research using the microbiota-based products currently under development in the MRT™ drug platform. Click on the title of the congress publication below to view complete details.

Researching RBX2660 and the Reduction of Clostridioides difficle Infection Recurrence

Improvement of MICROBIOME HEALTH INDEX™ in Patients with Recurrent Clostridiodes difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes

ASM Microbe 2019
June 20-24, 2019, San Francisco, CA

Response to Microbiota-Based Drug RBX2660 is Associated with Reduction in Antimicrobial Resistance Genes in Patients with Recurrent Clostridiodes difficile Infections

ASM Microbe 2019
June 20-24, 2019, San Francisco, CA

RBX7455 – A Non-frozen, Lyophilized, Oral Microbiota-based Drug Reduces Clostridrium difficile Infection Recurrence and Restores Patients’ Microbiomes

ACG 2018
October 5-10, 2018, Philadelphia, PA

Prevention of Recurrent Clostridium difficile at Six Months Following Treatment with Microbiota-based Therapy RBX2660: Durability Results From a Phase 2 Open-label Study

IDWeek 2018
October 3-7, 2018, San Francisco, CA

Evaluating a Prototype MICROBIOME HEALTH INDEX™ (MHI™) as a Measure of Microbiome Restoration Using Data Derived From Published Studies of Fecal Microbiota Transplant to Treat recurrent Clostridium difficile Infections (rCDI)

IDWeek 2018
October 3-7, 2018, San Francisco, CA

A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455

ASM Microbe 2018
June 7-11, 2018, Atlanta, GA

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype MICROBIOME HEALTH INDEX™

Digestive Disease Week (DDW)
June 2-5, 2018, Washington, DC

A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium difficile Infection Recurrence, and Restores the Microbiome

Digestive Disease Week (DDW)
June 2-5, 2018, Washington, DC

The Microbiota-based Drug RBX2660 is Efficacious and Safe in Patients with Recurrent Clostridium difficile Infections: Results from 2 Controlled Clinical Trials

28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21-24, 2018, Madrid, Spain

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation of a Prototype MICROBIOME HEALTH INDEX™

28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
April 21-24, 2018, Madrid, Spain

Altering the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile

World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL

Developing Microbiome Rehabilitation Biomarkers for Clostridium difficileInfections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)

World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL

There is No Association Between Patient Outcomes and Demographics in an Open-Label Safety and Efficacy Study of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection

World Congress of Gastroenterology @ ACG 2017
October 13-18, 2017, Orlando, FL

RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results

Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA

Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders

Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA

Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile

Infectious Diseases Week (ID Week)
October 4-8, 2017, San Diego, CA

Changing the Microbiome: Patients with a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjects’ Profile

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA

Resetting the Microbial Landscape: Donor Microbiome Engraftment in Patients Treated with RBX2660 for Multi-Recurrent Clostridium difficile Infection

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA

Meta-analysis of Response Rates Among Placebo-Treated Patients from Five Clinical Trials of Experimental Recurrent Clostridium difficile Therapeutics

ASM Microbe 2017
June 1-5, 2017, New Orleans, LA

Lack of Association with Patient Demographics and Outcomes in PUNCH CD 2, a Randomized Controlled Trial of RBX2660, a Microbiota-based Drug for Recurrent Clostridium difficile Infection

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Donors are Universal in the Fight Against Clostridium difficile: Results from Two Trials Investigating the Safety and Efficacy of RBX2660, a Microbiota-based Drug

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trial

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Durable Prevention of Recurrent C. difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Does the Donor Matter? Results from PUNCH CD 2, a Randomized Controlled Trial of a Microbiota-based Drug for Recurrent Clostridium difficile Infection

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results of the PUNCH CD 2 Trial

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA

Impact of RBX2660 on the Intestinal Microbiota of Patients with Recurrent Clostridium difficile Infection Enrolled in the Randomized, Placebo-Controlled PUNCH CD 2 Trial

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA

Placebo Responders in a Randomised Controlled Trial of RBX2660 for Recurrent C. Difficile Infection: Predictive Value of 16s rRNA Microbiome Analysis

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria

RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria

Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria

Increased Microbial Diversity Found in Successful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection

Gut Microbiota for World Health
March 5-6, 2016, Miami, FL

Infectious Threats in “Healthy” Donors: Results of a Donor Screening Program for a Next-Generation FMT

Gut Microbiota for World Health
March 5-6, 2016, Miami, FL

Increased Microbial Diversity Found in Successful vs. Unsuccessful Recipients of Next-Generation FMT for Recurrent Clostridium difficile Infection

Infectious Diseases Week 2015
October 7-11, 2015, San Diego, CA

Assessing Infectious Threats in “Healthy” FMT Donors: Results of an Assessment Program to Support a Next-Generation Drug for Recurrent Clostridium difficile Infection

Infectious Diseases Week 2015
October 7-11, 2015, San Diego, CA

Successful Implementation of a Phase 2 Study of a Novel Microbiota-based Drug for Recurrent Clostridium difficile Infection

Society of Gastroenterology Nurses and Associates
May 15–19, 2015, Baltimore, MD

Perspectives on the PUNCH CD Trial of a Microbiota-Based Drug Targeted at Recurrent C. difficile Infection

Society of Gastroenterology Nurses and Associates
May 15–19, 2015, Baltimore, MD

Does the Donor Matter? Donor vs. Patient Effects in the Outcome of Next-Generation Fecal Transplant for Recurrent Clostridium difficile Infection

Digestive Diseases Week
May 16–19, 2015, Washington, DC

Clearance of Vancomycin-Resistant Enterococcus Concomitant with Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection

European Congress of Clinical Microbiology and Infectious Diseases
April 25-28, 2015, Copenhagen, Denmark

Results of the Phase 2 PUNCH™ CD Safety Study of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

European Congress of Clinical Microbiology and Infectious Diseases
April 25-28, 2015, Copenhagen, Denmark

Enema Administration of RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: Lessons Learned from the PUNCH CD Study

American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA

RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA

Evaluation of Health-Related Quality of Life in Patients Treated with RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

American College of Gastroenterology
October 8-12, 2014, Philadelphia, PA

RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH™ CD Study

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Regulatory Considerations in Commercializing a Non-Antibiotic Microbiota-Based Drug Targeted for Recurrent Clostridium difficile Infection

Microbiome / Microbiota
R&D and Business Collaboration Forum
October 2-3, 2014, San Diego, CA

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT